FDA approves Bayer’s Kerendia for chronic kidney disease in type 1 diabetes
Bayer said the FDA approved Kerendia (finerenone) to treat adult patients with chronic kidney disease associated with type 1 diabetes, its third approved indication in the U.S.
Bayer said the FDA has approved Kerendia, also known as finerenone, for treatment of adult patients with chronic kidney disease associated with type 1 diabetes. The company said this is the third approved U.S. indication for Kerendia.